Acute respiratory distress syndrome (ARDS) is a pathological condition that involves diffuse lung injury and severe hypoxemia caused by pulmonary and systemic diseases. We have established a mouse model of severe ARDS, developed by intratracheal injection of a-galactosylceramide (a-GalCer), an activator of natural killer T (NKT) cells, followed by LPS. In the present study, we used this model to investigate the regulatory mechanism in the early inflammatory response during acute lung injury. In a-GalCer/LPS-treated mice, the number of CD4 þ CD25 þ Foxp3 þ regulatory T (Treg) cells and the expression of a Treg cell-tropic chemokine, secondary lymphoid-tissue chemokine (SLC), in the lungs was significantly lower than in mice treated with LPS alone. Giving recombinant (r)SLC increased the number of Treg cells in a-GalCer/LPS-treated mice. Treatment with anti-IFN-g mAb enhanced the expression of SLC and the accumulation of Treg cells in the lungs of a-GalCer/ LPS-treated mice, whereas giving recombinant (r)IFN-g reduced the number of Treg cells in mice treated with LPS alone. IL-10 production was significantly lower in a-GalCer/LPS-treated mice than in mice treated with LPS alone. Giving rIL-10 prolonged survival and attenuated lung injury as a result of reduced production of inflammatory cytokines (such as IL-1b, IL-6, TNF-a, and IFN-g) and chemokines (including MCP-1, RANTES, IP-10, Mig, MIP-2, and KC) in a-GalCer/LPS-treated mice. Treatment with anti-IFN-g mAb enhanced IL-10 production in a-GalCer/LPS-treated mice. These results suggest that the attenuated accumulation of Treg cells may be involved in the development of severe ARDS through a reduction in the synthesis of IL-10.
Acute respiratory distress syndrome is a clinical disease entity that involves diffuse lung injury and severe hypoxemia. This pathological condition is caused by a variety of pulmonary and systemic diseases, such as viral and bacterial pneumonia, aspiration of gastric juice into the lungs, near-drowning, severe trauma, and sepsis (1, 2) . The prognosis is poor and the mortality rate is high (approximately 25% to 30%), even in recent years with advanced medical treatment (1) . Levels of proinflammatory cytokines and chemokines, including IFN-g, TNF-a, IL-6, and IL-8, are elevated in the serum and BALF, indicating the strong involvement of the pulmonary inflammatory response in the pathogenic mechanism of ARDS (3) (4) (5) .
Giving systemic or intrapulmonary LPS has been widely used to establish an animal model of ARDS, in which a rapid and massive infiltration of inflammatory cells into the lungs is observed with the production of various proinflammatory cytokines and chemokines (6, 7) . In this model, however, the inflammatory changes are resolved several days after giving LPS, and there is neither diffuse alveolar damage nor hyaline membrane formation in the alveolar space, both of which are typical histological features of ARDS (8) . Recently, we established an animal model of severe ARDS by sensitizing mice through intratracheal instillation with a-GalCer, a potent activator of NKT cells, followed by a challenge dose of LPS by the same route (9) . In this model, the ARDS mice undergo a rapid and marked production of proinflammatory cytokines and chemokines in the lungs and a massive infiltration of inflammatory cells with the typical histological features of ARDS, leading to an early fatal outcome within 3 days. IFN-g and TNF-a are shown to play central roles in the development of this pathological condition (9) .
The inflammatory response is critically controlled by a variety of anti-inflammatory mechanisms, including immunoregulation by Treg cells, a subset of CD4 þ T cells that express the surface marker CD25, and the transcription factor Foxp3. This T-cell subset suppresses the activation and differentiation of various immune cells (10, 11) , and contributes to the regulation of the wide variety of immune responses against microorganisms, tumors, allergens, and transplantation-related antigens (10) (11) (12) (13) (14) . Treg cells exert these suppressive effects by secreting anti-inflammatory cytokines, such as IL-10 and transforming growth factor-b (TGF-b) (10, 11, 15, 16) . In previous studies, Treg cells were reported to be involved in the pathogenic mechanism during the development of acute lung injury caused by LPS (17) (18) (19) (20) .
In the present study, we used our model to examine the possible involvement of Treg cells in the development of severe ARDS. We showed that the production of SLC, a Treg cell-tropic chemokine (21) , and the accumulation of Treg cells is attenuated in the lungs of mice with severe ARDS. We also showed that giving rIL-10 prolongs survival, attenuates lung injury, and reduces the production of inflammatory cytokines and chemokines in these mice. These results suggest that impairment of the Treg cell-mediated anti-inflammatory mechanism may contribute to the exacerbation of acute lung injury.
MATERIALS AND METHODS

Ethics statement
This study was carried out in strict accordance with the Fundamental Guidelines for Proper Conduct of Animal Experiments and Related Activities in Academic Research Institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology in Japan, 2006. All experimental procedures involving animals followed the Regulations for Animal Experiments and Related Activities at Tohoku University, Sendai, Japan and were approved by the Institutional Animal Care and Use Committee at Tohoku University (approval numbers: 2012 IDOU-126, 2013 IDOU-099). All experiments were carried out under anesthesia, and all efforts were made to minimize the suffering of the animals.
Animals
C57BL/6 mice purchased from CLEA Japan (Tokyo, Japan) were used. Male mice at 7 to 8 weeks of age were used in the experiments. All mice were kept under specific pathogen-free conditions at the Institute for Animal Experimentation, Tohoku University Graduate School of Medicine. In all animal experiments, survival was monitored at least twice daily, and moribund animals, as indicated by decreased mobility/activity, lethargy, rough hair coat, weight loss greater than 25%, and hypothermia, were killed by isoflurane followed by cervical dislocation. There was no unexpected animal death. We used the humane endpoints as described above to kill the animals to minimize suffering and distress.
Reagents a-Galactosylceramide, purchased from Funakoshi (Tokyo, Japan), was dissolved in DMSO (Sigma-Aldrich, St Louis, MO, USA) at a concentration of 5 mg/mL and then diluted with PBS to a final concentration of 0.4% DMSO for in vivo use. LPS from Escherichia coli (O111: B4) was purchased from Sigma-Aldrich.
Severe ARDS model
A mouse model of severe ARDS was established, as previously described (9) . Mice were anesthetized using an i.p. injection of 70 mg/kg pentobarbital (Abbott Laboratories, North Chicago, IL, USA), restrained on a small board, and injected with 50 mL a-GalCer (1 mg) into the trachea using a 24-gauge catheter (TERUMO, Tokyo, Japan). Twenty-four hours later, 50 mL LPS (50 mg) was given by the same route. Control mice received 50 mL 0.4% DMSO-containing PBS instead of a-GalCer into the trachea and/or 24 hr later, 50 mL PBS instead of LPS was given using the same route.
Histological examination
Lung specimens obtained from mice were fixed in 10% buffered formalin, dehydrated, and embedded in paraffin. Sections were cut and stained with hematoxylin-eosin (HE) using standard staining procedures at the Biomedical Research Core, Animal Pathology Platform of Tohoku University Graduate School of Medicine. We measured histological evidence of tissue injury using the Lung Injury Scoring System recommended by the American Thoracic Society (ATS) (22) . Lung Injury Scoring System parameters include neutrophils in the alveolar space, neutrophils in the interstitial space, hyaline membranes, proteinaceous debris filling the airspaces, and alveolar septal thickening. At least 20 random high-power fields (400Â total magnification) were independently scored in a blinded fashion. The sum of each of the five independent variables were weighted according to the relevance ascribed to each feature by the ATS Committee, and were then normalized to the number of fields evaluated, as described in our recent study (23) .
Preparation of bronchoalveolar lavage fluids and lung interstitial leukocytes
Mice were killed at various intervals after LPS exposure. Their chests were opened, their tracheae were cannulated (22 G i.v. catheter), and 1 mL PBS was infused intratracheally and withdrawn. This procedure was carried out three times. BALF were centrifuged at 450 Â g for 10 min at 4°C, and the supernatant was stored at À80°C until cytokines were measured. After collecting the BALF, pulmonary circulation was rinsed by injecting 3 mL PBS into the right ventricle. Next, lungs were harvested and stored, either in 1.5 mL PBS for analysis of cytokines in the interstitial lung area or in the same volume of RPMI-1640 (Nipro, Osaka, Japan) medium supplemented with 10% FCS (BioWest, Nuaill e, France) for analysis of lung interstitial leukocytes. Lungs that were stored in PBS were homogenized and centrifuged at 450 Â g for 10 min at 4°C, and the supernatant was stored at À80°C until cytokine levels were measured. For surface antigen expression analysis, the homogenized lung cells were incubated for 60 min at 37°C with vigorous shaking in RPMI-1640 medium supplemented with 10 mM HEPES (Sigma-Aldrich) and 10% FCS containing 20 U/mL collagenase and 1 mg/mL DNase I (Sigma-Aldrich). Tissue fragments and dead cells were removed by passing the solution through a 40-mm nylon mesh. After centrifugation at 450 Â g for 5 min at 4°C, each cell pellet was resuspended in 4 mL of 40% (v/v) Percoll (Pharmacia, Uppsala, Sweden) and layered onto 4 mL of 80% (v/v) Percoll. After centrifugation at 450 Â g for 20 min at room temperature, the cells at the interface were collected, washed three times, and counted using a hemocytometer. Cells were concentrated onto microscope slides using cytospin (Iris Sample Processing, Westwood, MA, USA), stained with Diff-Quick stain (Sysmex, Kobe, Japan), and observed under a microscope. Number of lymphocytes was estimated by multiplying the total leukocyte number by their proportion.
Analysis of Treg cells by flow cytometry
Lung interstitial leukocytes were pre-incubated with anti-FcgRII/III mAb, which were prepared from the culture supernatants of hybridoma cells (clone 2.4G2) using a protein G column kit (Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA), on ice for 15 min in PBS containing 1% FCS and 0.1% sodium azide. The cells were stained using FITC-conjugated anti-CD4 (clone GK1.5; BD Biosciences, Franklin Lakes, NJ, USA) and Pacific Blue-conjugated CD25 (clone PC61; BioLegend, San Diego, CA, USA) or FITC-conjugated control rat IgG2ak (clone RTK2758; BioLegend) and Pacific Blue-conjugated control rat IgG1k (clone RTK2071; BioLegend). After the cell surface was stained, the cells were stained for intracellular Foxp3. The cells were fixed and permeabilized with Foxp3 staining buffer (e-Bioscience, San Diego, CA, USA), then stained with PE-conjugated Foxp3 mAb (clone FJK-16S; eBioscience) or control rat IgG2ak (clone RKT2758; BioLegend). The stained cells were analyzed using a flow cytometer (FACS Canto II; BD Biosciences). Live cells were selected using 7-amino-actinomycin D (7-AAD) viability staining solution (BioLegend). Data were collected from 30,000 individual cells using forward scatter (FSC) and side scatter (SSC) parameters to gate on the lymphocyte population. Number of Treg cells was estimated by multiplying the number of lymphocytes by the propor-
Measurement of cytokine concentrations
Concentration of cytokines was measured using an appropriate ELISA (BioLegend for IFN-g, IL-1b, IL-6 and IL-10; BD Bioscience for TNF-a; eBioscience for TGF-b).
Measurement of BALF protein
Protein concentration in BALF was measured using a bicinchoninic acid (BCA) protein assay reagent kit (Thermo Fischer Scientific K.K., Yokohama, Japan). The detection limit was 125 mg/mL.
Extraction of RNA and quantitative real-time RT-PCR
Total RNA was extracted from infected lungs using Isogen (Wako Pure Chemical, Osaka, Japan) and firststrand cDNA was synthesized using a PrimeScript 1 1st strand cDNA Synthesis Kit (Takara Bio Inc., Otsu, Japan), according to the manufacturer's instructions. Quantitative real-time PCR was carried out in a volume of 20 mL using gene-specific primers and FastStart Essential DNA Green Master (Roche Applied Science, Branford, CT, USA) in a LightCycler 1 Nano System (Roche Applied Science). The primer sequences for amplification are shown in Table 1 . The reaction efficiency with each primer set was determined using standard amplifications. Target gene expression levels and that of HPRT as a reference gene were calculated for each sample using the reaction efficiency. The results were analyzed using a relative quantification procedure and are presented as the relative expression compared with hypoxanthine phosphoribosyl transferase (HPRT) expression.
Giving anti-IFN-g antibody and cytokines
Anti-IFN-g mAb (125 mg, R4-6A2; BioLegend) was given i.p. 3 hr prior to LPS injection and 25 mg was given intratracheally at the time of LPS injection. Rat IgG (ICN Pharmaceuticals, Inc., Aurora, OH, USA) was used as a control antibody. Recombinant (r)IFN-g (200 ng; BioLegend) was given intratracheally 24 hr before LPS injection. rIL-10 (200 ng; BioLegend) was given intratracheally 0 hr and 12 hr after LPS injection. PBS was used as a control.
Statistical analysis
Data are expressed as the average and standard error. Statistical analysis between groups was carried out using analysis of variance with a Welch's t-test. Survival data were analyzed using the log-rank test. P-value < 0.05 was considered significant.
RESULTS
Attenuated accumulation of Treg cells in the lungs of mice with severe ARDS
Recently, we established a mouse model of severe ARDS in which much more severe lung injury occurred than in an LPS-induced acute lung injury (ALI) model (9) . In previous studies by D'Alessio and coworkers (17) , Treg cells were suggested to be involved in the resolution of tissue injury in a mouse model of acute lung injury caused by LPS. This suggested that dysfunction of these cells may be involved in the exacerbation of lung injury in our model. Thus, in the first experiments, we compared the kinetics of Treg cells by counting the number of CD4 þ CD25 þ Foxp3 þ cells in lung leukocytes prepared from mice treated with PBS/LPS or a-GalCer/ LPS at various time intervals after giving LPS. As shown in Figure 1 , the number of Treg cells was significantly reduced at 6, 12, and 24 hr in the a-GalCer/LPS group compared to the PBS/LPS group. These results suggest that attenuated accumulation of Treg cells may be involved in the development of severe ARDS caused by giving sequential a-GalCer and LPS.
Chemokine synthesis in the lungs of mice with severe ARDS
In Figure 1 , we show that Treg cells accumulated in the lungs of PBS/LPS-treated mice as early as 3 or 6 hr after LPS treatment, which suggests that this accumulation may be a result of the migration of natural Treg (nTreg) cells from the blood circulation, and not because of the development of inducible Treg (iTreg) cells at local sites. The migration of nTreg cells is known to be controlled by several chemokines, such as TARC, MDC, and SLC (22, 24, 25) . Therefore, we examined the expression of these chemokines in the lungs at 6, 12, and 24 hr after giving LPS. As shown in Figure 2a , SLC expression was significantly attenuated at every time point in the a-GalCer/LPS group compared to the PBS/LPS group, whereas there was no significant difference in the other chemokines. These results suggest that the reduced expression of SLC may hamper the accumulation of Treg cells in the lungs of mice with severe ARDS. To address this possibility, we next examined the effect of giving recombinant (r)SLC on the number of Treg cells in the lungs of a-GalCer/LPS-treated mice. As shown in Figure 2b , giving rSLC led to a striking increase in the number of Treg cells 6 hr after LPS treatment, when SLC expression and Treg cells started to decrease in a-GalCer/LPS-treated mice compared to PBS/LPStreated mice. 
Effect of giving rIL-10 on the development of ARDS
Immunoregulatory effects of Treg cells are mediated in part by IL-10 (10, 11, 15, 16). Therefore, we compared the production of IL-10 in the BALF and lung homogenates between PBS/LPS-and a-GalCer/LPS-treated mice. As shown in Figure 4 , the IL-10 concentration in both samples was significantly lower in the a-GalCer/LPS group than in the PBS/LPS group at 12 hr after treatment with LPS. These results suggest that IL-10 may be involved in the development of severe ARDS in a-GalCer/LPS-treated mice. We addressed this possibility by examining the effect of giving rIL-10 on the clinical course of ARDS. As shown in Figure 5a , giving rIL-10 completely rescued the a-GalCer/LPS-treated mice, 80% of which were dead within 72 hr under the PBS-treated condition in place of rIL-10. Histological analysis showed that the inflammatory response in the lungs of a-GalCer/ LPS-treated mice was significantly attenuated by rIL-10 compared to PBS treatment at 48 hr after LPS treatment, just before killing the a-GalCer/LPS-treated mice (Fig. 5b) ; this is also shown by the significantly lower lung injury score (Fig. 5c ) and by the strikingly reduced concentration of total protein in the BALF at 48 hr and 36 hr after LPS treatment, respectively (Fig. 5d) . 
Reduced cytokine and chemokine response by rIL-10 during the development of ARDS
Lung injury during the development of ARDS is critically regulated by proinflammatory cytokines and chemokine-induced recruitment of inflammatory leukocytes (9) . Therefore, we next examined the effect of giving rIL-10 on the production of IL-1b, IL-6, TNF-a, and IFN-g in BALF. As shown in Figure 6a , the production of these cytokines was significantly enhanced in the a-GalCer/LPS group compared to the PBS/LPS group at 12 hr after LPS treatment. Giving rIL-10 abrogated this increase in IL-1b, IL-6, and TNF-a production, whereas IFN-g production was partially suppressed by this treatment. Similarly, the expression of chemokines, such as MCP-1, RANTES, Mig, IP-10, and KC, in the lungs was significantly increased in the a-GalCer/LPS group compared to the PBS/LPS group at 24 hr after LPS treatment, and giving rIL-10 led to abrogation in the expression of RANTES and KC and to partial inhibition of Mig and IP-10 expression. The expression of MIP-2 was also strongly inhibited by rIL-10, although its expression did not differ significantly between the PBS/LPS and a-GalCer/LPS groups (Fig. 6b) . In previous investigations by Sittipunt and coworkers (26) , nitric oxide (NO) was suggested to be associated with the development of ARDS. We examined the expression of iNOS in the lungs in the current model. As shown in Figure 6b , the expression of iNOS mRNA was strikingly increased in the a-GalCer/LPS group compared to the PBS/LPS group at 24 hr after LPS treatment, and this increase was strongly inhibited by giving rIL-10. Effect of anti-IFN-g mAb on IL-10 production in mice with severe ARDS IFN-g is a critical cytokine in the development of severe ARDS in a-GalCer/LPS-treated mice (9), and it is involved in the suppression of Treg cell recruitment in these mice (Fig. 3a-c) . Therefore, we examined how neutralizing mAb against this cytokine affected the production of IL-10 in a-GalCer/LPS-treated mice. As shown in Figure 7 , giving anti-IFN-g mAb led to a striking increase of IL-10 production in the lungs at 12 hr after LPS treatment, whereas giving control rat IgG did not have this effect.
DISCUSSION
In the present study, we addressed the possible involvement of CD4 þ CD25 þ Foxp3 þ Treg cells and IL-10 in the pathogenesis of severe ARDS using a mouse model established by sensitization with a-GalCer and subsequent challenge with LPS. The main findings are as follows: (i) in a-GalCer/LPS-treated mice, the number of Treg cells and the expression of SLC, a Treg cell-tropic chemokine, in the lungs was significantly lower than in mice treated with LPS alone; (ii) giving rSLC increased the number of Treg cells in a-GalCer/LPS-treated mice; (iii) treatment with anti-IFN-g mAb enhanced the expression of SLC and the accumulation of Treg cells in the lungs of a-GalCer/LPS-treated mice, whereas giving rIFN-g reduced the number of Treg cells in mice treated with LPS alone; (iv) the production of IL-10 was significantly lower in a-GalCer/LPS-treated mice than in mice treated with LPS alone; (v) giving rIL-10 prolonged the survival and attenuated lung injury as a result of the reduced production of proinflammatory cytokines and chemokines in a-GalCer/LPS-treated mice; and (vi) treatment with anti-IFN-g mAb enhanced IL-10 production in a-GalCer/LPS-treated mice. These results suggest that the decreased accumulation of Treg cells may contribute to the development of severe ARDS through the reduction in IL-10 production.
Several studies have reported the role of Treg cells in the pathogenesis of acute lung injury (17) (18) (19) (20) . These reports focused on Treg cells in the BALF whereas in the current study, we addressed these cells in both the lung interstitium and in the BALF. In our study, it was difficult to detect lymphocytes in the BALF as early as within 24 hr after giving LPS, which was in agreement with a previous study (17) . Lymphocytes in the lung interstitium have not been investigated in previous studies using animal models of LPS-induced lung injury. In the current study, we observe that approximately 10% of all cells analyzed were lymphocytes and found an increase in the number of Treg cells in the lungs, including the interstitium, in a rapid phase after giving LPS. These data suggest the early accumulation of Treg cells before the acceleration of the inflammatory response in the lungs. In contrast, previous studies have reported the accumulation of Treg cells in alveolar spaces later than during the peak of the inflammatory response, which suggests that Treg cells in the alveolar spaces may be involved in the resolution of the inflammatory response and the repair of damaged tissues. Thus, Treg cells accumulating in the early and later phases may play different roles in the pathogenesis of acute lung injury.
Many studies have indicated the involvement of Treg cell infiltration at local sites during the development of various pathogenic conditions. The increased accumulation of Treg cells has been reported in cancer tissues, including ovarian cancer with a poor prognosis (27, 28) . In ovarian cancer, MDC, a ligand for CCR4, was shown to be involved in the accumulation of Treg cells expressing CCR4 (27) . In infection with Leishmania major, Treg cells have been shown to infiltrate the skin lesions in a method dependent on CCR5 (29) . In contrast, other studies have suggested the possible contribution of Treg cells to the pathogenic mecha nism of allergic, inflammatory, and autoimmune diseases (14, 30, 31) . These previous reports suggest that during the development of ARDS, the inflammatory process may be out of control under the reduced accumulation of Treg cells in lungs, which may be caused by the reduced production of chemokines. TARC and MDC, CCR4 ligands, and SLC, a CCR7 ligand, are known to contribute to the recruitment of Treg cells to cancer tissues and lymph nodes (21, 24, 32, 33) . In the current study, SLC synthesis was significantly lower in the severe ARDS model than in mice treated with LPS alone early after giving LPS, although there was no difference in the synthesis of TARC and MDC, suggesting the involvement of SLC rather than the other two chemokines. Ueha and coworkers (21) showed that Treg cells showed a stronger chemotaxis response to SLC than to TARC and MDC in an in vitro chemotaxis assay, which is compatible with our present results. SLC has also been reported to attract monocytes, dendritic cells, and Th1 cells in the lungs (33) (34) (35) (36) (37) . However, in our study, the expression of inflammatory chemokines, including MCP-1, Mig, and IP-10 (which attract monocytes and Th1 cells), was significantly higher in mice with severe ARDS than in mice treated with LPS alone, which was in striking contrast to SLC. Considered collectively, these results suggest the contribution of SLC to the recruitment of Treg cells, rather than monocytes and Th1 cells, in the early stage of acute lung injury.
In our earlier studies (9, 23), we showed that a large amount of IFN-g was produced in the lungs as soon as 6 hr after the LPS challenge in mice sensitized with a-GalCer. These findings suggest that this high level of IFN-g may play a critical role in the development of severe ARDS and that it may be strongly involved in the regulation of SLC production and the accumulation of Treg cells in the lungs. In agreement with this prediction, giving anti-IFN-g mAb resulted in a striking increase in SLC synthesis and the enhanced accumulation of Treg cells in the lungs of mice with severe ARDS. This was consistent with our previous findings that severe ARDS was almost completely improved by the treatment with anti-IFN-g mAb (9) . Additionally, the sensitization of mice with rIFN-g instead of a-GalCer led to the suppression of Treg cell accumulation after challenge with LPS, which was consistent with our previous data indicating the exaggerated inflammatory response in the lungs by this treatment (9) . Considered collectively, the current data suggest that the robust amount of IFN-g secreted after the pre-activation of NKT cells may trigger the drastic inflammation that leads to severe ARDS by suppressing SLC production and the accumulation of Treg cells in the lungs. To the best of our knowledge, no previous reports have indicated IFN-g-induced suppression of SLC production and the accumulation of Treg cells. To achieve a better understanding of the precise mechanism, further investigation is necessary to define the cellular source of SLC production and the effect of rIFN-g on this response.
Treg cells are known to secrete IL-10 to produce their anti-inflammatory effects (10, 11, 15, 16 ). In the current study, the production of this anti-inflammatory cytokine in the lungs of mice treated with LPS alone was significantly reduced by sensitizing them with a-GalCer. In our earlier studies, a robust amount of proinflammatory cytokines, such as TNF-a and IFN-g, was produced in the lungs as early as 6 hr after giving LPS in mice with severe ARDS (9, 23) . These findings suggest that the reduced production of IL-10 may contribute to increased inflammation in this model. Similarly, giving rIL-10 resulted in complete improvement of survival and the attenuation of histological lung injury in mice with severe ARDS. In addition, giving rIL-10 completely abrogated the production of TNF-a, IL-1b, and IL-6 to the basal level in the BALF of mice with severe ARDS, suggesting the suppression of these proinflammatory cytokines under treatment with rIL-10. Similarly, expression of iNOS was strongly inhibited by this treatment in the lungs of mice with severe ARDS, suggesting an improvement of this pathological condition by reduced production of NO, which was previously suggested to show a strong association with the development of ARDS (26) . Here, IFN-g synthesis was not completely abrogated by rIL-10 treatment in mice with severe ARDS, which was in contrast to other proinflammatory cytokines. Similarly, the expression of IFN-g-induced chemokines such as IP-10 and Mig (38) was partially, but not completely, inhibited by this treatment. Although the reason remains unclear, proinflammatory cytokines such as TNF-a, IL-1b, and IL-6 may play more critical roles than IFN-g in the development of fatal lung injury in our model.
It is known that Treg cells secrete another antiinflammatory cytokine, TGF-b (10, 11, 15, 16) . D'Alessio and coworkers reported the contribution of this cytokine to the resolution of lung injury mediated by Treg cells (17) . This finding suggests that the TGF-bmediated anti-inflammatory mechanism may be impaired under the decreased accumulation of Treg cells, which may be involved in the development of severe lung injury in our model. Similarly, the production of TGF-b in the lungs of mice treated with LPS alone was significantly attenuated by sensitizing these mice with aGalCer (Fig. S1 ). Further investigation is necessary to define the role of TGF-b in the pathogenic mechanism of severe ARDS.
The current study shows that SLC synthesis, accumulation of Treg cells and the anti-inflammatory response in the lungs were attenuated at an early phase in our mouse model of severe ARDS compared to mice treated with LPS alone, and these findings suggest that attenuated accumulation of Treg cells caused by reduced SLC synthesis may contribute to the progression of severe lung injury. In addition, IL-10 is suggested to act as an anti-inflammatory cytokine to suppress the development of an exaggerated inflammatory response, although we have not succeeded in determining the cellular source of this cytokine. These mechanisms are summarized in Figure 8 . Further studies are needed to investigate this potential mechanism. Thus, the current findings may provide important insights to advance the development of novel therapeutic strategies in ARDS. Fig. 8 . Possible mechanism for development of severe ARDS. In PBS/LPS-treated mice, lung tissues are injured at an acute phase after giving LPS, followed by SLC-induced accumulation of Treg cells which calms down the inflammatory response through production of IL-10. By contrast, in a-GalCer/LPS-treated mice, a large amount of IFN-g is produced by activated NKT cells, which causes attenuation in SLC-induced Treg cell accumulation and reduced production of IL-10. This mechanism may contribute to uncontrolled inflammatory response in the lungs, leading to severe ARDS. PBS/LPS, sensitized with PBS and challenged with LPS; a-GalCer/LPS, sensitized with a-GalCer and challenged with LPS.
